$COR

DURCAN DERMOT MARK purchased $1.1M of COR

DURCAN DERMOT MARK purchased 4,000 shares of Cencora, Inc. (COR) at $266.26 ($1.07M total) on 2026-05-28.

Original reporting
SEC EDGAR · DURCAN DERMOT MARK
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COR
Bullish
medium confidence
Mentioned
$COR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase of 4,000 shares at a stated price, which can marginally support sentiment but does not provide new guidance, earnings, or deal information.

02

Market read

Traders may note the insider buy as a small positive sentiment datapoint, but it is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not explain motivation, and insider buying alone rarely changes valuation without accompanying operational catalysts.

Relevance 7/10Novelty 4/10Timing: Filed 2026-05-28, after-hours/close timing for the same trading day.

Background

The article is an SEC Form 4 insider transaction disclosure for Cencora, Inc. (COR).

Company-level read

Ticker impact

$CORBullishMedium confidence
Context

Cencora Form 4 shows director Durcan Dermot Mark bought 4,000 shares at $266.26 on 2026-05-28, totaling $1.07M.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by broader disclosures.

Evidence & confidence

The filing is a primary-source insider transaction with clear size and price, but it does not include new company performance, strategy, or regulatory developments.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine, tax-related, or driven by personal liquidity needs, so they may not reflect a new fundamental outlook.

Key entities

  • Cencora, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • DURCAN DERMOT MARK

    Director who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

HighAI 9/10

Cencora Agrees to Take Controlling Stake in American Oncology Network in $2.4 Billion Deal Spanning 21 States

Cencora agreed to acquire American Oncology Network (AON) for $2.4 billion, expanding its oncology services. The deal, pending approval, includes $2.3 billion at closing plus up to $100 million in contingent value rights. Cencora already owns 4% of AON and aims to increase its stake to 75%. The acquisition is part of a broader trend of drug wholesalers buying cancer practice management companies.

$CORHighAI 9/10

Cencora to buy American Oncology Network in $2.4bn deal

Cencora (COR) agreed to acquire American Oncology Network (AON) for $2.4bn, including $2.3bn at closing and up to $100m in contingent value rights. COR shares fell 4.84% post-announcement, despite recent gains. The deal expands COR's oncology services into 12 new states. COR raised its fiscal 2026 EPS guidance to at least $17.90. The transaction requires regulatory approval and AON stockholder approval.

$CORHighAI 9/10

Cencora, Inc. (COR): Results of Operations and Financial Condition

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA TO ACQUIRE AMERICAN ONCOLOGY NETWORK TO STRENGTHEN SUPPORT OF COMMUNITY ONCOLOGY Builds on Cencora’s MSO platform by adding complementary capabilities and expanding presence across twelve additional states CONSHOHOCKEN, PA & FORT MYERS, Fla., October 21, 2026

$CORHighAI 9/10

Cencora to acquire American Oncology Network for $2.4 billion

Cencora Inc. (NYSE:COR) will acquire American Oncology Network Inc. (OTCQX:AONC) for $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The deal will expand Cencora's oncology services platform. Cencora expects the acquisition to be accretive to earnings per share by the second year post-closing and updated its 2026 EPS guidance to at least $17.90. The transaction is subject to regulatory approvals and AON stockholder approvals.

$CORHighAI 9/10

Cencora, Inc. (COR) to Acquire American Oncology Network for $2.4B EV

Cencora (COR) agreed to acquire American Oncology Network for $2.4B EV, with $2.3B paid at closing and up to $100M in contingent value rights. Cencora expects to pay about $1.7B for 75% ownership if 25% equity is rolled. The deal is expected to be EPS accretive in year two, subject to approvals. According to Cencora, the acquisition aligns with its strategy to expand in oncology services.

HighAI 8/10

Cancer-practice support would expand to 12 more states under Cencora's planned acquisition

Cencora plans to acquire American Oncology Network (AON), expanding its oncology services to 12 more states. The deal aims to enhance care access and support independent practices. Cencora expects the acquisition to be accretive to its adjusted diluted EPS in the second year post-closing. The transaction is subject to regulatory approvals and AON stockholder approvals.